← All trials
NCT05755854
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 3, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Mar 6, 2023
- Last posted
- Sep 22, 2023
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Medical UniversityLead sponsor
- Anhui Medical UniversityReponsible party - principal investigator
- Anhui Medical UniversityOfficial
- Anhui Medical UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.